Compare PAX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | SYRE |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2020 | 2015 |
| Metric | PAX | SYRE |
|---|---|---|
| Price | $11.95 | $40.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $20.00 | ★ $55.57 |
| AVG Volume (30 Days) | ★ 998.6K | 709.5K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $15.87 | N/A |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.44 | $10.91 |
| 52 Week High | $17.80 | $45.76 |
| Indicator | PAX | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 20.89 | 56.66 |
| Support Level | $10.12 | $14.62 |
| Resistance Level | $14.53 | $45.76 |
| Average True Range (ATR) | 0.48 | 2.35 |
| MACD | -0.09 | -0.24 |
| Stochastic Oscillator | 6.44 | 47.96 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.